Atopic Dermatitis / Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2024

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. It typically develops in early childhood and can persist into adulthood. The standard first-line treatment for AD is topical immunotherapy, which has proven broadly effective in managing symptoms. In topical-refractory patients, symptoms are commonly managed by systemic immunomodulators, which can have serious side effects when administered over the long term. The launches of Pfizer’s Eucrisa (crisaborole), Sanofi / Regeneron’s Dupixent (dupilumab), LEO Pharma’s Adbry (tralokinumab), two oral JAK inhibitors (AbbVie’s Rinvoq [upadacitinib] and Pfizer’s Cibinqo [abrocitinib]), and one topical JAK inhibitor (Incyte’s Opzelura [ruxolitinib]) have greatly expanded treatment options for pediatric patients with AD across the severity spectrum. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug treatment trends in pediatric AD.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
• How have Eucrisa, Dupixent, Adbry, and JAK inhibitors been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of pediatric AD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: LEO Pharma, Pfizer, Sanofi / Regeneron, Incyte, AbbVie

Key drugs: Adbry, Cibinqo, Dupixent, Eucrisa, Opzelura, Rinvoq

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses